KRAS early testing: Consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an italian setting

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Barone, Carlo ^a   Pinto, Carmine ^b   Normanno, Nicola ^c   Capussotti, Lorenzo ^d   Cognetti, Francesco ^e   Falcone, Alfredo ^f   Mantovani, Lorenzo ^g  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d MAURIZIANO HOSPITAL   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CONSENSUS; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; HEALTH CARE ACCESS; HIGH RISK PATIENT; HUMAN; ITALY; METASTATIC COLORECTAL CANCER; PHYSICIAN ATTITUDE; QUALITY ADJUSTED LIFE YEAR; RADICAL RESECTION; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; DELPHI STUDY; ECONOMICS; GENETICS; HEALTH CARE COST; METASTASIS; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DELPHI TECHNIQUE; HEALTH CARE COSTS; HUMANS; ITALY; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84921393402     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085897     Document Type: Article

References (36)

1. Winder T, Lenz HJ (2010) Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev 36: 550-556.
2. Dumpke WC, Heinemann V (2010) Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. Anticancer Res 30: 4673-4677.
3. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, et al. (2010) Tumour response and secondary respectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase II trial. Lancet Oncol 11: 38-47.
4. Petrelli F, Barni S, Anti-EGFR agents for liver metastases (2012) Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis 27: 997-1004.
5. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, et al. (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48: 1466-1475.
6. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, et al on behalf of the MRC COIN Trial Investigators (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377: 2103-2114.
7. Tveit KM, Guren T, Gimelius B, Pfeiffer P, Sorbye H, et al. (2012) Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 30: 1755-1762.
8. Mileshkin L, Shah B, Michael M (2012) Predictive molecular tumour testing: What are the obstacles between bench and bedside? Chemother Res Pract. Epub ahead of print. DOI: 10.1155/2012/838509.
9. Marchetti A, Pinto C, Taddei GL, Troncone G, Russo A, et al. (2011) KRAS mutations in colorectal cancer patients in Italy: Results from the KRAS aKtive program. J Clin Oncol 29 (suppl; abstr e14000).
10. Lièvre A, Artru P, Guiu M, Laurent-Puig P, Merlin JL, et al. (2013) The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011. Eur J Cancer. Epub ahead of print. DOI: 10.1016/j.ejca.2013.02.016.
11. Barone C, Belisari A, Ciardiello F, D'Angiolella L, Furneri G, et al. (2012) Cetuximab nel trattamento di prima linea del carcinoma metastatico del colonretto. Farmeconomia 13 (Suppl 1): 1-80.
12. Linstone H, Turoff M, eds. (1975) The Delphi Method. Techniques and Applications. Reading, MA: Addison-Wesley Publishing Company. 1-616.
13. Jones J, Hunter D (1995) Consensus methods for medical and health services research. BMJ 311: 376-380.
14. Rowe G, Wright G (1999) The Delphi technique as a forecasting tool: issues and analysis. International Journal of Forecasting 15: 353-375.
15. Graham B, Regehr G, Wright JG (2003) Delphi as a method to establish consensus for diagnostic criteria. J Clin Epidemiol 56: 1150-1156. (Pubitemid 37532800)
16. Fehr A, Thürmann P, Razum O (2011) Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Serv Res 11: 312.
17. Raijmakers NJ, van Zuylen L, Costantini M, Caraceni A, Clark JB, et al. (2012) Issues and needs in end-of-life decision making: an international modified Delphi study. Palliat Med 26: 947-953.
18. Uphoff EP, Wennekes L, Punt CJ, Grol RP, Wollersheim HC, et al. (2012) Development of generic quality indicators for patient-centered cancer care by using a RAND modified Delphi method. Cancer Nurs 35: 29-37.
19. Speksnijder HT, Mank AP, van Achterberg T (2011) Nursing diagnoses (NANDA-I) in hematology-oncology: a Delphi-study. Int J Nurs Terminol Classif 22: 77-91.
20. Expert Panel on Radiation Oncology-Prostate, Frank SJ, Arterbery VE, Hsu IC, Abdel-Wahab M, Ciezki JP, et al. (2011) American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. Brachytherapy 10: 357-362.
21. Danielson B, Brundage M, Pearcey R, Bass B, Pickles T, et al. (2011) Development of indicators of the quality of radiotherapy for localized prostate cancer. Radiother Oncol 99: 29-36.
22. Delva F, Marien E, Fonck M, Rainfray M, Demeaux JL, et al. (2011) Factors influencing general practitioners in the referral of elderly cancer patients. BMC Cancer 11: 5.
23. Moss EL, Owen G, Jones PW, Sarhanis P, Nordin A, et al. (2010) The British Gynaecological Cancer Society Delphi consultation exercise on expected standards of practice for doctors specializing in the area of gynaecological oncology. Int J Gynecol Cancer 20: 488-491.
24. Expósito J, Bretón JJ, Domínguez C, Pons J (2010) Controversies on the management of clinical situations with low therapeutic effectiveness in oncology. Clin Transl Oncol 12: 493-498.
25. Chan A, Tan SH, Wong CM, Yap KY, Ko Y (2009) Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. Clin Ther 31 Pt 2: 2379-2386.
26. Robson N, Rew D (2010) Collective wisdom and decision making in surgical oncology. Eur J Surg Oncol 36: 230-236.
27. Gagliardi AR, Simunovic M, Langer B, Stern H, Brown AD (2005) Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach. Can J Surg 48: 441-452. (Pubitemid 43117094)
28. NICE technology appraisal guidance 176. Cetuximab for the first-line treatment of metastatic colorectal cancer. Issue date: August 2009; Review date: August 2012. Available: http://www.nice.org.uk/nicemedia/pdf/ta176guidance.pdf. Accessed 2 September 2013.
29. Scottish Medicines Consortium No. 543/09 - Cetuximab, 100 mg/20 mL and 500 mg/100 mL solution for intravenous infusion (Erbitux®). Available: http://www.scottishmedicines.org.uk/files/cetuximab-Erbitux-RESUBMISSION-FINAL- January-2010-for-website.pdf. Accessed 2 September 2013.
30. Loblaw DA, Prestrud AA, Somerfield MR, Oliver TK, Brouwers MC, et al. (2012) American Society of Clinical Oncology Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol 30: 3136-3140.
31. Amado RG, Wolff M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
32. Garcia-Foncillas J (2012) Determina KRAS: A consolidated project. J Clin Oncol 30 (suppl 4; abstr 428).
33. Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, et al. (2012) Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer 131: 438-445.
34. Asseburg C, Frank M, Köhne C-H, Hartmann JT, Griebsch I, et al. (2011) Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther 33: 482-497.
35. Shankaran V, Bentrem DJ, Mulcahy MF, Bennett CL, Benson ABIII (2009) Economic implication of Kras testing in metastatic colorectal cancer (mCRC). ASCO 2009 Gastrointestinal Cancers Symposium. Abstract No: 298. San Francisco, CA, 2009.
36. Behl AS, Goddard KAB, Flottemesch TJ, Veenstra D, Meenan RT, et al. (2012) Cost-effectiveness analysis of screening of KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 104: 1785-1795.